Key limitations of GLP-1 therapies have driven the swift development of differentiated assets for the treatment of obesity
Miller, Ralph Green and Ari J
Interim findings from a mixed-methods, multi-site study Joseph Lanario 1 , Nicola Anderson 1 , Olalekan Lee Aiyegbusi 1 , Ameeta Retzer 1 , Foram Khatsuria 1 , Nancy Bhardwaj 1 , Sarah Hughes 1 , Christel McMullan 1 , Flic Gaete Carvajal 1 , Philip Collis 1 , Roger Wilson 1 , Kamil Sterniczuk 1 , Yvonne Yalder 1 , Sarah Markham 1 , Emily Lam 1 , Clarice McKay 1 , Ian Clarke 1 , Robert Michell 1 , John Rose 1 , Samantha Drewett 1 , Melanie Calvert 1 1 University of Birmingham, Birmingham, UK Journal of Patient-Reported Outcomes 2026 , 10(Suppl 1) :210.3 Aims Patient-Reported Outcomes (PROs) can provide valuable insights into the impact of disease and treatment from the patient perspective
We expect MHRA approval and UK availability around mid-July 2026